RedTalks #5: CD19 CAR T cells for B-cell NHL and CLL: lessons learnt and next steps
Access the replay of the RedTalks #5
Date: February 4th, 2021, at 6 pm CET, in english
- Dr Jordan GAUTHIER, Fred Hutch/University of Washington, SEattle/Washington, USA
- Publications: Blood, Blood, Bone Marrow Transplant.
- Pr Guillaume CARTRON, CHU Montpellier, France
- Emmanuel GOMEZ, R&D director of CALYM
We are delighted to welcome Dr. Jordan Gauthier who will provide you insightful information on lessons learned by the use of CAR T cells in early clinical trial.
Dr Jordan Gauthier will review the lessons learned after treating nearly 200 patients with relapsed or refractory B-cell malignancies on a phase I/II clinical of defined composition CD19 CAR T-therapy. The factors associated with efficacy, duration of response, and toxicity will be discussed. Finally, the strategies to further improve outcomes of CD19 CAR T-cell therapy, such as repeat infusions of CAR T cells and the concurrent administration of ibrutinib with CD19 CAR T-cell therapy in ibrutinib-refractory CLL patients, will be explored.
This Redtalk will be hosted by Pr. Guillaume Cartron and Emmanuel Gomez.
Dr Jordan GAUTHIER